Table 3.
Clinical characteristics of reported cases of synchronous hepatocellular carcinoma (HCC) and lymphoma in the literature.
| References | Age (year) | Gender | Lymphoma | Hepatocellular carcinoma | Chemotherapy regimens | OS (months) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | Staging | Treatment | Diagnosis | Number | Hepatitis virus infection | Treatment | |||||
| Suriawinata et al. (5) | 55 | Male | DLBCL | Not described | – | Well-differentiated HCC | 2 | HCV | Liver transplantation | Not described | >15 |
| Kataoka et al. (6) | 64 | Male | DLBCL | Not described | Conservative therapy | Well-differentiated | 1 | HCV | Conservative therapy | – | 1.5 |
| Lin et al. (7) | 70 | Male | DLBCL | Not described | Chemo | Necrotic tumor tissue with few HCC cells | Multiple | HCV | Not described | R-CHOP | NA |
| Lee et al. (8) | 60 | Male | FL | Not described | Chemo | HCC | 2 | HCV | TACE and RFA | R-CVP | >20 |
| Present case | 58 | Male | DLBCL | III | Chemo | Well-differentiated | 1 | HBV | Hepatolobectomy | CHOP | >62 |
FL, follicular lymphoma; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; DLBCL, diffuse large B-cell lymphoma; Chemo, chemotherapy; Ope, operation; OS, overall survival; R-CHOP, rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; HBV, hepatitis B virus; HCV, hepatitis C virus.